Biosimilars: An Approach to some Current Worldwide Regulation Frameworks

Author(s): Efraín Esteban, Rosa-Helena Bustos*, Julio-César García, Edwin Jáuregui.

Journal Name: Current Clinical Pharmacology

Volume 14 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Developing new biologics has led to regulations and norms aimed at guaranteeing their safety, quality and effectiveness, in terms of marketing, prescription, use, interchangeability and switching. Biologics are of great importance in treating patients suffering from rheumatic, autoimmune, inflammatory and neoplastic diseases. The expiry/lapse of reference biologics or originators’ patents has meant that developing biosimilars involves accompanying legal requirements for their approval in countries worldwide. This paper has thus approached the situation of biosimilar regulation worldwide, the pertinent technical concepts and regulatory differences in some countries of interest.

Keywords: Biosimilar, biologic, biotechnological drug/biopharmaceutical, monoclonal antibody, cytokines, coagulation factors.

[1]
Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimi- lars. Ann Oncol 2008; 19(3): 411-9.
[2]
Ibarra-Cabrera R, Mena-Perez SC, Bondani-Guasti A, et al. Re- view on the worldwide regulatory framework for biosimilars focus- ing on the Mexican case as an emerging market in Latin America. Biotechnol Adv 2013; 31(8): 1333-43.
[3]
Zuniga L, Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol 2010; 56(3): 374-7.
[4]
Reichert JM. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany. MAbs 2011; 3(3): 223-40.
[5]
Knezevic I, Griffiths E. Biosimilars--global issues, national solu- tions. Biologicals 2011; 39(5): 252-5.
[6]
Panesar K. Biosimilars: Current Approvals and Pipeline Agents. US Pharm 2016; 41(10): 26-9.
[7]
Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 2006; 11(4): 341-6.
[8]
Manrique S, Jiménez W. Mercado de medicamentos biotecnológicos en el Sistema General de Seguridad Social en Salud Ciencia y Tecnología para la Salud Visual y Ocular 2012; 10(2): 59-78.
[9]
Schellekens H. Follow-on biologics: challenges of the “next gen- eration”. Nephrol Dial Transplant 2005; 20(Suppl. 4): iv31-6.
[10]
Choy E, Jacobs IA. Biosimilar safety considerations in clinical practice. Semin Oncol 2014; 41(Suppl. 1): S3-S14.
[11]
Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regula- tion of biosimilars: current status and future challenges. BioDrugs 2013; 27(3): 203-11.
[12]
Generics and Biosimilars Initiative - GaBi. Biosimilar on the horizon. http://www.gabionline.net/Biosimilars/General/Biosimilarson-the-horizon2017. (accessed on 12 August 2017) .
[13]
Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009. 2(Suppl_1): i27-i36
[14]
Association EGM. Biosimilar Medicines Handbook http://www. medicinesforeurope.com/wp- content/uploads/2016/04/BIOSIMILAR-MEDICINES-HANDBOOK_INT_web_links2.pdf2016. (accessed on 21 September 2017).
[15]
Shein-Chung C. Biosimilars Design and Analysis of Follow-on Biologics. 2014; p. 411.
[16]
Gómez-Ramírez O, Gómez-Ramírez A. Calidad de vida, nivel de salud percibido y factores sociodemográficos en personas con artri- tis reumatoide. Aquichan 2016; 17(2): 150-61.
[17]
Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther 2018; 47(3): 356-63.
[18]
Iughetti L, Tornese G, Street ME, et al. Long-term safety and effi- cacy of Omnitrope(R), a somatropin biosimilar, in children requir- ing growth hormone treatment: Italian interim analysis of the PATRO Children study. Ital J Pediatr 2016; 42(1): 93.
[19]
Cozijnsen MA, Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Paediatr Drugs 2018; 20(1): 19-28.
[20]
Kostic M, Djakovic L, Sujic R, et al. Inflammatory Bowel Diseases (Crohn s Disease and Ulcerative Colitis): Cost of Treatment in Ser- bia and the Implications. Appl Health Econ Health Policy 2017; 15(1): 85-93.
[21]
Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73(1): 198-206.
[22]
Cuñeti L. Generalidades de los Medicamentos BiológicosBoletín Farmacológico 2014; Bh http://www.boletinfarmacologia.hc.edu.uy/index.php?option=com_content&task=view&id=104&Itemid=66 (accessed on 18 August 2017).
[23]
Organization WH. WHO Expert Committee on Biological Standardization. http://www.who.int/biologicals/WHO_TRS_963.pdf2011.
[24]
Thomas J. Follow-On Biologics. The Law and Intellectual Property Issues Congressional Research Service 2014.
[25]
Johnson J. Biologics and Biosimilars: Background and Key Issues. Congressional Research Service 2017.
[26]
Revers L, Furczon E. An Introduction to Biologics and Biosiilars. Part I: Biologics: What are they and where do they come from? Can Pharm J 2010; 143(3): 134-9.
[27]
US Food and Drug Administration. What is a biological product? https://www.fda.gov/aboutfda/transparency/basics/ucm194516.htm2017. (accessed on 15 June 2017).
[28]
Rodney JY, Gibaldi M. Biotechnology and Biopharmaceuticals.Transforming Proteins and Genes into Drugs. 1a. ed.;. 2013; p. p. 633.
[29]
World Health Organization. Biotherapeutics Products http://www. who.int/biologicals/vaccines/biotherapeutic-products/en/2013.
[30]
Walsh G. Pharmaceuticals, biologics and biopharmaceuticals. In Biopharmaceuticals: Biochemistry and Biotechnology, Wiley-Blackwell, Ed England, . 2003; Vol. Second Edition.
[31]
Pineda C, Castaneda Hernandez G, Jacobs IA, et al. Assessing the Immunogenicity of Biopharmaceuticals. BioDrugs 2016; 30(3): 195-206.
[32]
Islam R. Bioanalytical challenges of biosimilars. Bioanalysis 2014; 6(3): 349-56.
[33]
Rodney JY, Gibaldi M. Application of Biotechnology in Drug Discovery and Early Development.In Biotechnology and Biopharmaceuticals:Transforming Proteins and Genes into Drugs, 2aed; Wiley-Blackwell, Ed. 2013; p. p. 633.
[34]
Cooper R. Understanding and Incentivizing Biosimilars http://repository.uchastings.edu/faculty_scholarship2012. accessed on 3 August 2017)
[35]
Bhupinder S, Vikrant S. Biosimilars: an overview. Biosimilars 2011; 1: 1-11.
[36]
Blackstone EA, Fuhr JP Jr. Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosim-ilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012; 9(1): 24-7.
[37]
Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clini- cians should know. Blood 2012; 120(26): 5111-7.
[38]
Berghout A. Clinical programs in the development of similar bio- therapeutic products: rationale and general principles. Biologicals 2011; 39(5): 293-6.
[39]
Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007; 30(5): 267-72.
[40]
Camacho LH, Frost CP, Abella E, et al. Biosimilars 101: consid- erations for U.S. oncologists in clinical practice. Cancer Med 2014; 3(4): 889-99.
[41]
Walenga JM, Jackson CM, Kessler CM. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Semin Thromb Hemost 2011; 37(3): 322-7.
[42]
Cassell GH. Interactions of the public and private sectors in drug development: boundaries to protect scientific values while preserving innovation. Cleve Clin J Med 2007. 74 Suppl 2: S45-48; discussion S51-49.
[43]
Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 2013; 13(2): 153-6.
[44]
Gupta SK, Shukla P. Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review. Front Pharmacol 2017; 8: 419.
[45]
Al-Sabbagh A, Olech E, McClellan JE, et al. Development of biosimilars. Semin Arthritis Rheum 2016; 45(5)(Suppl.): S11-8.
[46]
Jimenez-Pichardo L, Gazquez-Perez R, Sierra-Sanchez JF. Degree of prescriber’s knowledge about variability in biological drugs “in- nova-tors” in manufacturing process. Eur J Clin Pharmacol 2018; 74(4): 505-11.
[47]
Deloitte. Advanced Biopharmaceutical Manufacturing: An Evolution Underway. https://www2.deloitte.com/content/dam/Deloitte/ us/Documents/life-sciences-health-care/us-lshc-advanced- biopharmaceutical-manufacturing-white-paper-051515.pdf2015. (accessed on 11 July 2017).
[48]
van de Weert M, Moller E. Immunogenicity of Biopharmaceuticals. 2008. (accessed on 4 August 2017)
[49]
US Food and Drug Administration. Pharmaceutical cGMPs for the 21st century: a risk-based approach. http://www.drugs.com/news/ fda-launches-21st-century-pharmaceutical-good-manufacturing- initiative-1240.html2002. (accessed on 12 August 2017)
[50]
Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009; 27(1): 26-34.
[51]
US Food and Drug Administration Guidance for industry: Q8 pharmaceutical development US Department of Health and Human Service. 2006.
[52]
US Food and Drug Administration. Guidance for industry: Q9 quality risk management US Department of Health and Human Service. 2006.
[53]
US Food and Drug Administration. Guidance for industry: Q10 quality systems qpproach to pharmaceutical cGMP regulations. 2006.
[54]
Endrenyi L, Declerck PJ, Chow S. Biosimilar Drug Product Devel- opment. 1st ed. CRC Press: Boca Raton. 2017.
[55]
Cohen SN, Chang AC, Boyer HW, et al. Construction of biologi- cally functional bacterial plasmids in vitro. Proc Natl Acad Sci USA 1973; 70(11): 3240-4.
[56]
Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007; 78(3): 183-205.
[57]
Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252(15): 5558-64.
[58]
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J Immunol 2005; 174(5): 2453-5.
[59]
Kinch MS. An overview of FDA-approved biologics medicines. Drug Discov Today 2015; 20(4): 393-8.
[60]
Olech E. Biosimilars: Rationale and current regulatory landscape. Semin Arthritis Rheum 2016; 45(5)(Suppl.): S1-S10.
[61]
US Food and Drug Administration Scientific Considerations in Demonstrating Biosimilarity to a Reference ProductGuidancy for Industry https://www.fda.gov/downloads/drugs/guidances/ucm 291128.pdf2015. (accessed on 12 August 2017).
[62]
European Medicines Agency. Guideline on similar biological medicinal products http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2014/10/WC500176768.pdf2014. (accessed on 12 August 2017).
[63]
WHO WHO. Guidelines of Evaluation fo Similar Biotherapeutics Products (SBPs). http://www.who.int/biologicals/areas/biological_ thera-peu- tics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf2009. (accessed on 12 August 2017)
[64]
Sandoz. Improving access to biologic medicines through biosimilars. https://www.sandoz.com/print/210412016.
[65]
Institute B. Biotechnology Timeline http://www.biotechinstitute. org/go.cfm?do=Page.View&pid=222017. (accessed on 12 August 2017).
[66]
Glassman RH, Sun AY. Biotechnology: identifying advances from the hype. Nat Rev Drug Discov 2004; 3(2): 177-83.
[67]
Li EC, Abbas R, Jacobs IA, et al. Considerations in the early de- velopment of biosimilar products. Drug Discov Today 2015; 20(Suppl. 2): 1-9.
[68]
Health Canada. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp- mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb- pbu-2016-eng.pdf2010. (accessed on 3 June 2017).
[69]
Wang J, Chow SC. On the regulatory approval pathway of biosimi- lar products. Pharmaceuticals (Basel) 2012; 5(4): 353-68.
[70]
World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs) http://www.who.int/biologicals/biotherapeutics/WHO_TRS_1004_web_Annex_2.pdf?ua=1 2016 (accessed on 12 August 2017)
[71]
Korea Food and Drug Administration. Guidelines on the Evaluation of Similar Biotherapeutic Products (SBPs). 2009.
[72]
MHLW Guidelines for the quality, safety and efficacy Assurance of follow-on biologics https://www.pmda.go.jp/files/000153851. pdf2009. (accessed on 25 September 2017)
[73]
Secretaría de Gobernacion-Diario Oficial de la Federación.DECRETO por el que se adiciona un artículo 222 Bis a la Ley General de Salud. http://www.dof.gob.mx/nota_detalle.php? Codigo= 5094117&fecha=11/06/20092009. (accessed on 12 August 2017).
[74]
Agência Nacional de Vigilância Sanitária-ANVISA. Registro de Productos Biológicos http://portal.anvisa.gov.br/documents/ 33840/324316/Registro_Produtos_Biologicos_Hemoterapicos_101 02011_WEB.pdf/047d205a-8b17-4316-9dd5-a6def6589e8b2011. (accessed on 12 August 2017).
[75]
Castanheira LG, Barbano DB, Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals 2011; 39(5): 308-11.
[76]
de la Cruz C, de Carvalho AV, Dorantes GL, et al. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America. J Dermatol 2017; 44(1): 3-12.
[77]
Ministerio de Salud de Políticas Regulación e Institutos - ANMAT.Disposición 7075 de 2011 http://www.anmat.gov.ar/webanmat/ reti-ros/octubre/Disposicion_7075-2011.pdf2011. (accessed on 15 June 2017).
[78]
Ministerio de Salud de Políticas Regulación e Institutos - ANMAT.Disposición 7729 de 2011 http://www.anmat.gov.ar/webanmat/ reti-ros/noviembre/Disposicion_7729-2011.pdf2011. (accessed on 15 August 2017).
[79]
Chile MdSRd. Norma Técnica 170 http://www.ispch.cl/sites/ default/files/Norma%20Biotecnologicos.pdf2014. (accessed on 24 August 2017)
[80]
Rathore A. Guidelines on similar biologics: regulatory require- ments for marketing authorization in India. PDA J Pharm Sci Technol 2012; 66(5): 393.
[81]
Central Drugs Standard Control Organisation - CDSCO. Guidance for Industry http://www.cdsco.nic.in/writereaddata/CDSCO- Guidance-ForIndustry.pdf2015. (accessed on 12 August 2017).
[82]
Department of Health Republic of South Africa. Biosimilar Medicines Quality, Non-Clinical and Clinical Requirements http:// www.mccza.com/documents/d259816c2.30_biosimilars_aug14_v3. pdf2014. (accessed on 1 July 2017).
[83]
Australian Government Department of Health. Australian Regulatory Guidelines for Biologicals (ARGB). http://www.tga.gov.au/ publica-tion/australian-regulatory-guidelines-biologicals-argb2011.
[84]
Pineda C, Caballero-Uribe CV, de Oliveira MG, et al. Recommen- dations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol 2015; 34(4): 635-40.
[85]
Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21(Suppl. 5): v13-6.
[86]
Bui L, Taylor C. Developing Clinical Trials for Biosimilars. Semin Oncol 2014; 41(Suppl. 1): S15-25.
[87]
Dranitsaris G, Dorward K, Hatzimichael E, et al. Clinical trial design in biosimilar drug development. Invest New Drugs 2013; 31(2): 479-87.
[88]
Kessler M, Goldsmith D, Schellekens H. Immunogenicity of bio- pharmaceuticals. Nephrol Dial Transplant 2006; 21(Suppl. 5): v9-v12.
[89]
Fernandez L, Bustos RH, Zapata C, et al. Immunogenicity in Pro- tein and Peptide Based-Therapeutics: An Overview. Curr Protein Pept Sci 2018; 19(10): 958-71.
[90]
US Food and Drug Administration. Guidance for Industry: Good¶ Pharmacovigilance Practices and Pharmacoepidemiologic Assesment. https://searchworks.stanford.edu/view/115699532005. (accessed on 16 July 2017).
[91]
Grampp G, Felix T. Pharmacovigilance Considerations for Biosimilars in the USA. BioDrugs 2015; 29(5): 309-21.
[92]
Calvo B, Leyre Z. Risk Management Plan and Pharmacovigilance System - Biopharmaceuticals: Biosimilars. In Business, Manage- ment and Economics.Risk Management Trends. Nota, G., Ed. 2011.
[93]
Mysler E, Pineda C, Horiuchi T, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biol- ogics in rheumatology. Rheumatol Int 2016; 36(5): 613-25.
[94]
Stevenson JG. Clinical data and regulatory issues of biosimilar products. Am J Manag Care 2015; 21(16)(Suppl.): s320-30.
[95]
Rompas S, Goss T, Amanuel S, et al. Demonstrating Value for Biosimilars: A Conceptual Framework. Am Health Drug Benefits 2015; 8(3): 129-39.
[96]
European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutics Proteins. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500003946.pdf2007. (accessed on 16 July 2017).
[97]
European Medicines Agency. Biosimilars in the EU. Information guide for healthcare professionals. http://www.ema.europa.eu/docs/ en_GB/document_library/Leaflet/2017/05/WC500226648.pdf2017. (accessed on 16 July 2017).
[98]
European Medicines AgencyEuropean Medicines Agency t to accept biosimilar reference medicines sourced outside European Economic Area http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_ev ents/news/2012/09/news_detail_001615.jsp&mid=WC0b01ac058004d5c12012. (accessed on 16 July 2017)
[99]
Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of Biosimilars: A European Perspective. BioDrugs 2017; 31(2): 83-91.
[100]
Rovira J, Espín J, García L, et al. The Impact of Bioimilars' entry in the EU Market. http://citeseerx.ist.psu.edu/viewdoc/down-load;jsessionid=E55994C2410E5147F6D56AFDA94BAAA0?doi=10.1.1.357.2218&rep=rep1&type=pdf 2011. (accessed on 16 July 2017).
[101]
Portela M, Sinogas C, Albuquerque de Almeida F, et al. Biologi- cals and biosimilars: safety issues in Europe. Expert Opin Biol Ther 2017; 17(7): 871-7.
[102]
Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One 2017; 12(12): e0190147.
[103]
European Medicines Agency. Guideline on Similar Biological Medicines Products containing Monoclonal Antiboides -non- Clinical and Clinical Issueshttp: www.ema.europa.eu/docs/ en_GB/ document_library/Scientific_guideline/2012/06/WC500128 686.pdf2012. (accessed on 16 July 2017).
[104]
Reinisch W, Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 2015; 44(6)(Suppl.): S9-S15.
[105]
Álvarez A, Mysler E, Ruíz E, et al. Recommendations for the Regulation of Biosimilars and their Iplementation in Latin Amer- ica. Gener-ics and Biosimilars Initiative Journal. GaBi J 2014; 3(3): 143-8.
[106]
Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons Rheumatology (Oxford). 2017. 56(suppl_4): iv49-iv62
[107]
Daller J. Biosimilars: A consideration of the regulations in the United States and European union. Regul Toxicol Pharmacol 2016; 76: 199-208.
[108]
Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol 2015; 8(5): 649-59.
[109]
Generics and Biosimilars Initiative - GaBi. Biosimilars use in Europe Generics and Biosimilars Initiative Journal (GaBi Journal). 2011.http://www.gabionline.net/Reports/Biosimilars-use-in-Europe (accessed on 16 July 2017)
[110]
Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory tra- jectory in the United States. Clin Ther 2012; 34(2): 400-19.
[111]
European Medicines Agency. European Public Assesment Report (EPAR)-Omnitrope. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
[112]
_Summary_for_the_public/human/000607/WC500043689.pdf 2008. (accessed on 16 July 2017).
[113]
Saenger P. Ten years of biosimilar recombinant human growth hormone in Europe. Drug Des Devel Ther 2017; 11: 1505-7.
[114]
van Meer PJ, Ebbers HC, Kooijman M, et al. Contribution of ani- mal studies to evaluate the similarity of biosimilars to reference prod-ucts. Drug Discov Today 2015; 20(4): 483-90.
[115]
Grozdanova A, Ancevska K, Sterjev Z, et al. Biosimilar Medical Products -Licensing, Pharmacovigilance and Interchangeability. De Gruy-ter Open 2016; 37(1): 27-36.
[116]
Kim YS, Choi BW, Yang SW, et al. Biosimilars: Challenges and Parth Forward. Biotechnol Bioprocess Eng; 2014; 19(5): 755-65.
[117]
Lopez-Siguero JP, Pfaffle R, Chanson P, et al. Ten years’ clinical experience with biosimilar human growth hormone: a review of ef- ficacy data. Drug Des Devel Ther 2017; 11: 1489-95.
[118]
Romer T, Saenger P, Peter F, et al. Seven years of safety and effi- cacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. Horm Res 2009; 72(6): 359-69.
[119]
Fuhr U, Tuculanu D, Berghout A, et al. Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for recon- stitution of Omnitrope and Genotropin. Eur J Endocrinol 2010; 162(6): 1051-8.
[120]
Pavlovic M, Girardin E, Kapetanovic L, et al. Similar biological medicinal products containing recombinant human growth hor- mone: European regulation. Horm Res 2008; 69(1): 14-21.
[121]
Romer T, Peter F, Saenger P, et al. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest 2007; 30(7): 578-89.
[122]
Lopez-Siguero J, Borras Perez MV, Balser S, et al. Long-term safety and efficacy of the recombinant human growth hormone Om-nitrope(R) in the treatment of Spanish growth hormone defi- cient children: results of a phase III study. Adv Ther 2011; 28(10): 879-93.
[123]
Borras Perez V, Lopez-Siguero JP, Martinez G, et al. A follow-up study to monitor adult height among Spanish children with growth hor-mone deficiency who received biosimilar human recombinant growth hormone (Omnitrope(R)) during a phase III clinical trial. Adv Ther 2015; 32(2): 148-56.
[124]
Schwarz HP, Birkholz-Walerzak D, Szalecki M, et al. One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age. Biol Ther 2014; 4(1-2): 1-13.
[125]
Pfäffle R, Schwab KO, Marginean O, et al. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope((R)) in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 2013; 4(1): 3-11.
[126]
Beck-Peccoz P, Minuto F, Leal-Cerro A, et al. Rationale and de- sign of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope((R)) for the treat- ment of adult patients with growth hormone deficiency. Ther Adv Endocrinol Metab 2012; 3(3): 85-91.
[127]
Pfäffle R, Kanumakala S, Höybye C, et al. Four-Year Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment. Poster presented at: the 55th Annual Meeting of the European Society for Paediatric Endocrinology 2016
[128]
Borras Perez MV, Kristrom B, Romer T, et al. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data. Drug Des Devel Ther 2017; 11: 1497-1503.
[129]
[130]
Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, et al. A randomized, double-blind study to assess the efficacy and safety of valtro-pin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 2007; 68(6): 288-93.
[131]
Sorgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characteri- zation, phar-macodynamics, and pharmacokinetics. BioDrugs 2015; 29(2): 123-31.
[132]
US Food and Drug Administration. Neupogen® (Filgrastim) https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/10335 3_5127lbl.pdf2010.(accessed on 24 July 2017).
[133]
Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tu- mours. Eur J Cancer 2011; 47(1): 8-32.
[134]
Blackwell K, Semiglazov V, Krasnozhon D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, ran- domized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppres- sive chemotherapy. Ann Oncol 2015; 26(9): 1948-53.
[135]
Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96(7): 937-42.
[136]
Welte KG-CSF. filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther 2014; 14(7): 983-93.
[137]
European Medicines Agency. Filgrastim Hexal http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_ the_public/human/000918/WC500022469.pdf2014. (accessed on 24 July 2017).
[138]
del Giglio A, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of se- vere neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemo- therapy. BMC Cancer 2008; 8: 332.
[139]
Agarwal AB, McBride A. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar. Crit Rev Oncol Hematol 2016; 104: 98-107.
[140]
Jelkmann W. Regulation of erythropoietin production. J Physiol 2011; 589(Pt 6): 1251-8.
[141]
European Medicines Agency. Binocrit Epoetin alfa http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_ for_the_public/human/000725/WC500053613.pdf2016. (accessed on 24 July 2017)
[142]
Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treat- ment of anemia in chronic renal failure patients receiving hemo- dialysis. Clin Nephrol 2009; 72(5): 380-90.
[143]
Rosti G, Petrini M, Bosi A, et al. Management of anaemia in onco- haematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. Ther Adv Med Oncol 2017; 9(1): 22-32.
[144]
Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correc- tion of renal anaemia. Curr Med Res Opin 2008; 24(5): 1407-15.
[145]
Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the mainte- nance phase of renal anaemia treatment. Curr Med Res Opin 2008; 24(3): 625-37.
[146]
Wiecek A, Ahmed I, Scigalla P, et al. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther 2010; 27(12): 941-52.
[147]
Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equiva- lence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010; 27(2): 105-17.
[148]
Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treat- ment in Nephrology. Am J Nephrol 2017; 45(3): 235-47.
[149]
Horbrand F, Bramlage P, Fischaleck J, et al. A population-based study comparing biosimilar versus originator erythropoiesis- stimulating agent consumption in 6,117 patients with renal anae- mia. Eur J Clin Pharmacol 2013; 69(4): 929-36.
[150]
Annese V, Vecchi M. Italian Group for the Study of IBD Use of biosimilars in inflammatory bowel disease: Statements of the Ital- ian Group for Inflammatory Bowel Disease. Dig Liver Dis 2014; 46(11): 963-8.
[151]
Feagan BG, Choquette D, Ghosh S, et al. The challenge of indica- tion extrapolation for infliximab biosimilars. Biologicals 2014; 42(4): 177-83.
[153]
[154]
Blair HA, Deeks ED. Infliximab Biosimilar (CT-P13; Infliximab- dyyb): A Review in Autoimmune Inflammatory Diseases. BioDrugs 2016; 30(5): 469-80.
[155]
Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, mul- ticentre, parallel-group, prospective study comparing the pharma- coki-netics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72(10): 1605-12.
[156]
Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coad- ministered with methotrexate in patients with active rheumatoid ar- thritis: the PLANETRA study. Ann Rheum Dis 2013; 72(10): 1613-20. (accessed on 24 July 2017).
[157]
Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals 2016; 44(4): 257-66.
[158]
Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Pa- tients with Inflammatory Bowel Disease in Real Life at 6 Months. Dig Dis Sci 2017; 62(5): 1305-12.
[159]
Gulacsi L, Brodszky V, Baji P, et al. Biosimilars for the manage- ment of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol 2015; 11(Suppl. 1): S43-52.
[160]
Brodszky V, Rencz F, Pentek M, et al. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Re- pub-lic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res 2016; 16(1): 119-25.
[161]
Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76(1): 58-64.
[162]
Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. Clin Gastroenterol Hepatol 2016; 14(12): 1685-96.
[163]
Saenger P. Current status of biosimilar growth hormone. Int J Pediatr Endocrinol 2009; 2009: 370329.
[164]
Skrlin A, Radic I, Vuletic M, et al. Comparison of the physico- chemical properties of a biosimilar filgrastim with those of refer- ence filgrastim. Biologicals 2010; 38(5): 557-66.
[165]
Grampp G, Ramanan S. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders. BioDrugs 2015; 29(6): 365-72.
[167]
[168]
US Food and Drug Administración. Science and the Regulation of Biological Products. https://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/100YearsofBiologicsRegulation/ucm070022.htm 2017.
[169]
Wong AY, Rumore MM, Chan AW. Biosimilars in the United States: Emerging Issues in Litigation. BioDrugs 2017; 31(3): 189-205.
[170]
Woodcock J, Griffin J, Behrman R, et al. The FDA’s assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 2007; 6(6): 437-42.
[171]
US Food and Drug Administration. Biologics Price Competition and Innovation Act https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf 2009.
[172]
US Food. and Drug Administración. Biosimilars Guidances. (accessed 13th Oct 2017)
[173]
US Food and Drug Administración. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product -Guidance for Industry. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf 2016.
[174]
us Food and Drug Administración. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 - Guidance for Industry. https://www.fda.gov/downloads/drugs/guidances/ucm444661.pdf2015.
[175]
] US Food and Drug Administración. Draft Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act. https://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm40 7844.pdf2014.
[176]
Kingham R, Klasa G, Carver K. Key Regulatory Guidelines for the Development of Biologics in the United States and Europe.In Biological Drug Products: Development and Strategies, Wang, W., Ed.John Wiley & Sons: 2014; pp. pp. 75-109.
[177]
US Food and Drug Administración. Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry-Draft Guidance. https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/UCM5371352017.
[178]
Us Food and Drug Administración Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. ttps://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm411418.htm2017.
[179]
US Food and Drug Administration. Labeling for Biosimilars Products-Guidance for Industry. https://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM493439.pdf2018.
[181]
Nabhan C, Parsad S, Mato AR, et al. Biosimilars in Oncology in the United States: A Review. JAMA Oncol 2017.
[182]
Camacho LH. Current Status of Biosimilars in Oncology. Drugs 2017; 77(9): 985-97.
[183]
Rugo H, Barve A, Waller C, et al. HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl- 1401O versus herceptin. Eur J of Cancer 2017; 72(S1): S41.
[184]
Stenina M, Ignatova E, Frolova M, et al. Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Her-ceptin in patients. Ann of Oncol 2016; 27(6): 68-00.
[185]
Generics and Biosimilars Initiative - GaBi. Biosimilars of bevacizumab http://gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab2017.
[186]
Generics and Biosimilars Initiative - GaBi. Subsequent entry biologics approved in Canada. http://www.gabionline.net/Biosimilars/ Gen-eral/Subsequent-entry-biologics-approved-in-Canada2017.
[187]
Furlanetto A, Purcell N. Biologics and biosimilars: a legal perspec- tive from Canada. Pharm Pat Anal 2016; 5(2): 79-81.
[188]
Kay J, Feagan BG, Guirguis MS, et al. Health Canada/ BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals 2012; 40(6): 517-27.
[190]
Bennett CL, Chen B, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 2014; 15(13): e594-605.
[191]
Bas TG, Oliu Castillo C. Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Ma- lay-sia-Overview, Evolution, and Regulations Assessment. BioMed Res Int 2016; 2016: 5910403.
[192]
Generics and Biosimilars Initiative - GaBi. Biosimilar development and regulation in Japan. GaBi J 2013; 2(4): 207-8.
[193]
Nagasaki M, Ando Y. Clinical development and trial design of biosimilar products: a Japanese perspective. J Biopharm Stat 2014; 24(6): 1165-72.
[194]
Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lym- phoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; 4(8): e362-73.
[195]
Jois R. The brave new world of biosimilars (‘similar biologics’) in India. Postgrad Med J 2017; 93(1104): 577-9.
[196]
Rushvi P, Charmy K, Nirav C, et al. Biosimilars: an Emerging Market Opportunities in India. Pharm Regul Aff 2016; 5(1): 1-7.
[197]
Government of India. Guidelines on Similar Biologics: Regulatory Requierements for Marketing Authorization in India. http:// dbtbiosafe-ty.nic.in/Files%5CCDSCO-DBTSimilarBiologicsfinal2012.
[198]
Castaneda-Hernandez G, Szekanecz Z, Mysler E, et al. Biopharma- ceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 2014; 81(6): 471-7.
[200]
Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016; 19(11): 1157-68.
[201]
Rajagopalan M, Mital A. Biologics use in Indian psoriasis patients. Indian Dermatol Online J 2016; 7(6): 489-97.
[202]
Suh SK, Park Y. Regulatory guideline for biosimilar products in Korea. Biologicals 2011; 39(5): 336-8.
[203]
Ministry of Food and Drug Safety. Biosimilar http://www.mfds. go.kr/eng/index.do?nMenuCode=1832017.
[204]
Sung Y-K, Cho S-K, Choi C-B, et al. Characteristics and outcomes of RA patients who start biosimilar infliximab in South Korea.[ab- stract no. 1221]. Arthritis Rheumatol 2015; 67(S10)
[205]
Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimi- lar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 2015; 9(Suppl. 1): 35-44.
[206]
Ministry of Health Malaysia NPCB. Guidance Document and Guidelines for Registration of Biosimilars in Malaysia http://npra. moh.gov.my/images/Guidelines_Central/Guidelines_on_Regulator y/GUIDELINES%20FOR%20REGISTRATION%20OF%20BIOSI MILAR%20(1).pdf2008.
[207]
Khoo Y, Tang T, Goh P, et al. An Update on the Registration of Biosimilars in Malaysia. Therapeutic Innovation & Regulatory Science 2017; 51(1): 55-9.
[208]
Generics and Biosimilars Initiative - GaBi. Biosimilar production in Malaysia http://www.gabionline.net/Biosimilars/News/Biosimilarproduction-¶ in-Malaysia 2015.
[209]
Abas A. Regulatory guidelines for biosimilars in Malaysia. Biologicals 2011; 39(5): 339-42.
[210]
Australian Government Department of Health. Why are biosimilar medicines important? http://www.health.gov.au/internet/main/ publish-ing.nsf/Content/biosimilar-why-are-biosimilar-medicinesimportant2017.
[211]
Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: world- wide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol 2017; 177(6): 1495-502.
[212]
Sturm M. Regulation Policy for Cell and Tissue Therapies in Aus- tralia. Tissue Eng Part A 2015; 21(23-24): 2797-801.
[213]
Generics and Biosimilars Initiative - GaBi. Biosimilars approved in Australia http://www.gabionline.net/Biosimilars/General/Biosimilarsapproved-in-Australia2017.
[214]
Lamb YN, Scott LJ, Deeks ED. SB2: An Infliximab Biosimilar. BioDrugs 2017; 31(5): 461-4.
[215]
Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 2015; 11(12): 713-24.
[216]
Castro-Ayarza J, González C, Velásquez-Lopera M, et al. Actuali- zación en biosimilares: una reflexión sobre la reglamentación en Co-lombia de los medicamentos biológicos y biosimilares. Rev Asoc Colomb Dermatol 2015; 23(1): 23-9.
[217]
Rondón F, Bautista F, Salazar A, et al. Etanar therapy in real-life patients with rheumatoid arthritis. [Abstract] Arthritis Rheumatol 2010; 62.
[218]
Vargas-Burgos R, Catoggio L, Maldonado-Galarza C, et al. Cur- rent therapies in rheumatoid arthritis: A Latin American perspec- tive. Reumatol Clin 2013; 9: 106-12.
[219]
Ministerio de Salud y Protección Social. Decreto 1782 de 2014 https://www.minsalud.gov.co/Normatividad_Nuevo/Decreto%2017 82%20de%202014.pdf2014.
[220]
Ministerio de Salud y Protección Social-República de Colombia.Guía de Evaluación de Inmunogenicidad de Medicamentos Biológicos. https://www.minsalud.gov.co/sites/rid/Lists/Biblioteca Digital/RIDE/DE/DIJ/2016-02-29guia-inmunogenicidad-consulta- omc.pdf2016.
[221]
Ministerio de Salud y Protección Social-República de Colombia.Resolución 0553 de 2017. https://www.minsalud.gov.co/ Normativi-dad_Nuevo/Resoluci%C3%B3n%20No.%2000553%20de%202017.pdf2017.
[222]
Ministerio de Salud y Protección Social-República de Colombia.Circular 015 de 2017 https://www.minsalud.gov.co/sites/rid/Lists/ Biblio-tecaDigital/RIDE/DE/DIJ/circular-15-de-2017.pdf2017.
[223]
Ministerio de Salud y Protección Social. Decreto 677 de 1995 https://www.invima.gov.co/images/pdf/medicamentos/decretos/dec re-to_677_1995.pdf1995.
[224]
Generics and Biosimilars Initiative - GaBi. Colombia issues further draft guidelines for biologicals http://www.gabionline.net/ Guide-lines/Colombia-issues-further-draft-guidelines-for-biologicals2015.
[225]
Casadevall N, Edwards IR, Felix T, et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther 2013; 13(7): 1039-47.
[226]
Ministerio de Salud y Protección Social-República de Colombia.Guía de Estabilidad de Medicamentos Biológicos - Borrador. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RID E/VS/MET/Guia-estabilidad-medicamentos-biologicos.pdf2015.
[227]
Secretaría de Gobernacion-Diario Oficial de la Federación.PROYECTO de Norma Oficial Mexicana PROY-NOM-257-SSA1-2013. http://www.dof.gob.mx/nota_detalle.php?codigo=5298031& fecha=06/05/20132013.
[228]
Mysler E, Scheinberg M. Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol 2012; 31(9): 1279-80.
[229]
Agência Nacional de Vigilância Sanitária-ANVISA. Resolução RDC 55 de 16 de dezembro de 2010. http://portal.anvisa.gov.br/ docu-ments/33880/2568070/res0055_16_12_2010.pdf/7e0571b2-5d9b-4a92-b844-d9b665b185c42010.
[230]
Agência Nacional de Vigilância Sanitária-ANVISA. Resolução RDC 49 de 2011. http://pfarma.com.br/noticia-setor-farmaceutico/ legisla-cao-farmaceutica/756-rdc-49-2011-medicamento- biologico.html2010.
[231]
Generics and Biosimilars Initiative - GaBi. Biosimilarity in Latin America. GaBi J 2013; 2(2): 94-6.
[232]
Agência Nacional de Vigilância Sanitária-ANVISA GpRdEdCpRdPBV. Guia para Realização do Exercício de Comparabilidadepara Regis- tro de Produtos Biológicos (Versão 1.1). ortal.anvisa.gov.br/ resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=2873340&_101_type=document 2016.
[233]
Yamaguchi T, Arato T. Quality, safety and efficacy of follow-on biologics in Japan. Biologicals 2011; 39(5): 328-32.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [16 - 40]
Pages: 25
DOI: 10.2174/1574884713666181025142928

Article Metrics

PDF: 32
HTML: 4
EPUB: 2
PRC: 2